Group 1 - The board meeting of Yifeng Pharmacy Chain Co., Ltd. was held on August 14, 2025, with all nine directors present and no dissenting votes [1][2] - The board unanimously approved all agenda items during the meeting, indicating strong consensus among the directors [1][2] - The company plans to apply for a bank credit limit for its wholly-owned subsidiary, Hubei Yifeng Pharmacy Chain Co., Ltd., with the credit limit being subject to bank approval and available for revolving use [2] Group 2 - The meeting was convened by Chairman Gao Yi and followed legal and regulatory procedures, ensuring the validity of the resolutions made [1] - The decision to waive the notice period for the board meeting was made due to the urgency of the matters being discussed [1] - The proposal for bank credit will be submitted for shareholder approval in the upcoming meeting [2]

Group 1 - The company held the 14th meeting of the 5th Supervisory Board on August 14, 2025, in Changsha, Hunan Province, with all three supervisors present and voting [1][2][3] - The meeting was convened and chaired by Mr. Chen Bin, the chairman of the Supervisory Board, and all resolutions passed were deemed legal and effective [1][3] - The Supervisory Board approved a proposal for the wholly-owned subsidiary, Hubei Yifeng Pharmacy Chain Co., Ltd., to apply for a bank credit limit, which is subject to bank approval and can be reused within the credit period [2]

Group 1 - The company announced an increase in temporary proposals for the second extraordinary general meeting of shareholders scheduled for August 25, 2025 [1][2] - The proposal to be added is regarding the company's guarantee for a subsidiary's bank credit application, submitted by a major shareholder holding 19.88% of the shares [2][3] - The original notice of the shareholders' meeting remains unchanged aside from the added proposal [2][3] Group 2 - The meeting will take place at 14:30 on August 25, 2025, at the company's logistics park in Changsha, Hunan Province [2][3] - Online voting will be available through the Shanghai Stock Exchange's system on the same day, with specific voting time slots outlined [2][3] - The equity registration date for the shareholders' meeting remains unchanged [3]

Core Viewpoint - Yifeng Pharmacy announced the approval of the proposal to waive the notification period for the 14th meeting of the fifth supervisory board [2] Group 1 - The fifth supervisory board of Yifeng Pharmacy held its 14th meeting on August 14 [2] - The meeting included the review and approval of the proposal regarding the waiver of the notification period [2]

（文章来源：证券日报） 证券日报网讯 8月14日晚间，益丰药房发布公告称，公司第五届董事会第二十次会议审议通过了《关于 豁免第五届董事会第二十次会议通知时限的议案》等。 ...

Group 1 - The core point of the article is that Yifeng Pharmacy announced its total external guarantee amounting to 261,500,000 yuan, which represents 24.38% of the company's most recent audited net assets [2][2][2] - The company confirmed that there are no overdue guarantees as of the announcement date [2][2][2]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 第五届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、 董事会会议召开情况 益丰大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 13 日以 电子邮件方式发出第五届董事会第二十次会议通知，会议于 2025 年 8 月 14 日在 湖南省长沙市金洲大道 68 号益丰医药物流园四楼会议室以现场加通讯方式召开， 应参加表决的董事 9 人，实际参加表决的董事 9 人，公司监事和高级管理人员列 席了会议，本次会议的召集、召开和表决程序符合有关法律、法规和《公司章程》 的规定，会议形成的决议合法有效。 二、 董事会会议审议情况 本次会议由董事长高毅先生召集并主持，采用记名投票方式，审议并通过了 如下议案： 公司为全资子公司湖北益丰大药房连锁有限公司向银行申 ...

2024年1至12月份，益丰药房的营业收入构成为：医药零售占比88.06%，医药批发占比8.76%，其他业 务占比3.19%。 （文章来源：每日经济新闻） 益丰药房（SH 603939，收盘价：23.71元）8月14日晚间发布公告称，截至本公告披露日，公司对外担 保总额度为26.15亿元，均为对合并报表范围内子公司的担保，占公司最近一期经审计净资产的 24.38%，不存在逾期担保的情形。 ...

（文章来源：每日经济新闻） 益丰药房（SH 603939，收盘价：23.71元）8月14日晚间发布公告称，公司第五届第二十次董事会会议 于2025年8月14日在湖南省长沙市金洲大道68号益丰医药物流园四楼会议室以现场加通讯方式召开。会 议审议了《关于豁免第五届董事会第二十次会议通知时限的议案》等文件。 2024年1至12月份，益丰药房的营业收入构成为：医药零售占比88.06%，医药批发占比8.76%，其他业 务占比3.19%。 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-075 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于为子公司申请银行授信提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●被担保人名称：湖北益丰大药房连锁有限公司（以下简称"湖北益丰"）， 为益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）全资子公司。 ●本次预计担保情况：公司为湖北益丰向银行申请总额不超过 30,000.00 万元 综合授信额度提供连带责任担保。 ●本次担保是否有反担保：无 ●对外担保的逾期累计数量：无 ●特别风险提示：本次提供担保对象湖北益丰资产负债率超过 70%，请投资 者注意投资风险。 一、担保情况概述 1、担保基本情况及履行决策程序 公司于 2025 年 8 月 14 日召开的第五届董事会第二十次会议以 9 票同意，0 票反对，0 票弃权审议通过了《关于公司为子公司申请银行授信提供担保的议 ...